Investment analysts at Royal Bank Of Canada started coverage on shares of Bruker (NASDAQ:BRKR – Get Free Report) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set a “sector perform” rating and a $66.00 price target on the medical research company’s stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 6.28% from the company’s current price.
Other research analysts have also issued research reports about the company. Zacks Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Citigroup lifted their price objective on shares of Bruker from $53.00 to $64.00 and gave the company a “hold” rating in a report on Thursday, November 5th. JPMorgan Chase & Co. lowered shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research note on Wednesday, October 14th. The Goldman Sachs Group raised Bruker from a “strong sell” rating to a “strong-buy” rating in a report on Monday, September 21st. Finally, Guggenheim boosted their target price on Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $61.00.
Bruker Stock Performance
Shares of NASDAQ:BRKR opened at $62.10 on Friday. The company has a market capitalization of $9.48 billion, a price-to-earnings ratio of -56.45, a price-to-earnings-growth ratio of 1.84 and a beta of 1.26. The company has a quick ratio of 0.90, a current ratio of 1.84 and a debt-to-equity ratio of 0.74. Bruker has a 52 week low of $32.37 and a 52 week high of $68.98. The firm has a 50 day moving average of $59.93 and a 200 day moving average of $51.25.
Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.14. Bruker had a positive return on equity of 13.76% and a negative net margin of 3.82%. The business had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same period in the prior year, the firm posted $0.45 earnings per share. The business’s quarterly revenue was up 1.6% on a year-over-year basis. On average, sell-side analysts predict that Bruker will post 2.13 earnings per share for the current fiscal year.
Insider Activity
In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 27.20% of the company’s stock.
Hedge Funds Weigh In On Bruker
A number of hedge funds and other institutional investors have recently made changes to their positions in BRKR. Global Retirement Partners LLC bought a new position in Bruker in the second quarter valued at approximately $38,000. Provenance Wealth Advisors LLC acquired a new stake in Bruker in the third quarter valued at about $52,000. Root Financial Partners LLC bought a new stake in shares of Bruker during the third quarter worth $57,000. Essential Partners LLC bought a new position in Bruker in the 1st quarter valued at approximately $36,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Bruker during the second quarter worth about $60,000. 79.52% of the stock is owned by institutional investors.
Bruker Company Profile
Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.
Featured Articles
- Five stocks we like better than Bruker
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
